GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$45.66 USD
+0.49 (1.08%)
Updated May 14, 2024 04:00 PM ET
After-Market: $45.65 -0.01 (-0.02%) 6:42 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.66 USD
+0.49 (1.08%)
Updated May 14, 2024 04:00 PM ET
After-Market: $45.65 -0.01 (-0.02%) 6:42 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA.
Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
by Zacks Equity Research
Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.
4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017
by Zacks Equity Research
Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.
Merck (MRK) Does Well in 2016: Reasons for Outperformance
by Zacks Equity Research
Merck & Co. Inc.'s (MRK) share price is up 12.1%, so far this year.
Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.
Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.
Big Pharma Face Off: Is Merck More Attractive than J&J?
by Zacks Equity Research
Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.
The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts
Is Brexit a Buying Opportunity?
by Tracey Ryniec
Value investors should keep an eye on what is going on in Great Britain right now.
Q2 Earnings Checklist Keeps Rolling Out: BA, CMCSA, GSK & Others
by Mark Vickery
After a busy session after the bell yesterday, including strength from Apple, we see another long list of reporting companies this morning.
CDXS and LOGI are Aggressive Growth Stocks
by Brian Bolan
Biotech supply chain and computer peripherals are the focus
Bull of the Day: Codexis (CDXS)
by Brian Bolan
Think of this stock as the supply chain to big biotech and that is driving huge earnings growth.